Immune Pharmaceuticals, Inc.
150 Broadway
Suite 1801
New York
New York
10038
United States
Tel: 646-937-1941
Website: http://immunepharmaceuticals.com/
149 articles about Immune Pharmaceuticals, Inc.
-
Acquisition of Immune Pharmaceuticals - Mar 29, 2021
3/29/2021
Immune Pharmaceuticals Inc has received an unconditional offer by United General LTD. to acquire control of Immune Pharmaceuticals Inc.'s public company.
-
Immune Pharmaceuticals Inc Announces Immune Pharmaceuticals Proposal to Exit Bankruptcy
3/18/2021
Immune Pharmaceuticals Inc. is in early-stage discussions with United General LTD, a UK Institutional Investment firm. Immune Pharmaceuticals Incs trustee and representatives are exploring options to restructure the company with United General LTD.
-
The season surrounding Valentine’s Day brings out the love in many people, but for two pharma companies, this year was a year of heartbreak. California-based Aradigm Corporation and New Jersey-based Immune Pharmaceuticals both filed Chapter 11.
-
Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update
11/15/2017
The Company recorded no revenue for the three-month periods ended September 30, 2017 and 2016.
-
Immune Pharmaceuticals Inc. Announces Closing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants
10/24/2017
Immune Pharmaceuticals Inc. announced the closing of its previously announced public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Immune.
-
Immune Pharma Announces Pricing of $18M Public Offering of Convertible Preferred Stock and Warrants
10/20/2017
The offering will be comprised of units, priced at a public offering price of $1,000 per unit.
-
Immune Pharma Rockets On Phase II Bertilimumab Trial Data
9/27/2017
-
Immune Pharma Receives NASDAQ Letter
8/30/2017
-
Immune Pharma Provides R&D And Business Update And Summary Of Recent Financial Highlights
8/28/2017
-
Immune Pharma Appoints Tony Fiorino, MD, PhD As Chief Medical Officer And Chief Operating Officer
8/14/2017
-
Cytovia, Inc., Immune Pharma’s Oncology Subsidiary, Announces Publication Of Results Showing Anti-Metastatic Properties Of Its Lead Drug Ceplene And Filing Of A New Worldwide Patent
8/10/2017
-
Cytovia, Inc., Immune Pharma’s Oncology Subsidiary, Announces The Publication Of New Results In The British Journal Of Haematology And Filing Of A World-Wide Patent Protecting The Use Of Ceplene In Chronic Myeloid Leukemia (CML)
8/7/2017
-
Immune Pharma Issues Letter To Shareholders
8/4/2017
-
Immune Pharma Provides Update On Plan To Implement A Spin-Off Of Cytovia, Inc. Into A Separate Publicly Traded Oncology Company
7/19/2017
-
Immune Pharma’ Oncology Subsidiary, Cytovia, Inc., Announces The Filing Of A World-Wide Patent Protecting The Use Of Ceplene In Acute Myeloid Leukemia (AML) And Other Hematological Cancers With Mutated NPM1
7/13/2017
-
Cytovia, Inc., Immune Pharma’ Oncology Subsidiary, Enters Into A Definitive Agreement With Pint Pharma For The Licensing And Commercialization Of Ceplene In Latin America
7/12/2017
-
Immune Pharma's Oncology Subsidiary, Cytovia, Inc., Announces Additional Clinical Trial Results On The Efficacy Of Ceplene In Combination With Low-Dose IL-2 In Patients With Acute Myeloid Leukemia
7/5/2017
-
Immune Pharma's Oncology Subsidiary, Cytovia, Inc. Provides Update To Proposed Pint Pharma Transaction: Substantial Agreement Reached On Material Terms Of The Licensing And Commercialization Of Ceplene In Latin America
6/29/2017
-
Immune Pharma Announces Initiation Of Enrollment In Clinical Trial With Ceplene/ Low-Dose IL-2 In Chronic Myelomonocytic Leukemia (CMML)
6/20/2017
-
Immune Pharma Receives NASDAQ Compliance Letter
6/19/2017